Medical Health & Life Science Research News

New release: Akt/Protein Kinase B Inhibitors to witness significant growth due to positive clinical results in the coming years

Akt/Protein Kinase B Inhibitors

Akt/Protein Kinase B inhibitors therapeutics currently exhibits a proliferating pipeline with 23 therapeutic candidates.

Akt plays a critical role in the regulation of cell’s apoptotic pathway and it is being studied extensively for targeting cancerous cells. Akt inhibitors are therapeutics that obstruct the Akt pathways or Akt enzyme, which play a key role in proliferation of solid tumors or cancer cells.

Akt are composed of various AGC kinases present in the cells that have hydrophobic motif at the c-terminus of their catalytic core.

The companies who are developing Akt/PKB inhibitors for the treatment of various chronic diseases have shown positive clinical results in the various phases of drug development. For instance, in June 2018, F. Hoffman-La Roche Ltd.

announced the interim results of Phase II study (LOTUS) for the drug candidate, ipatasertib, that showed improvement in patients with triple negative breast cancer (TNBC) toward overall survival (OS). This result was presented in the 2018 ASCO Annual Meeting, held in the U.S.

The Phase II LOTUS study showed an increase in OS up to 23.1 months (median) in interventional study, as compared to 18.4 months (median) in placebo study.

Download report sample at:

It has been observed that many pharmaceutical companies are leveraging new and improved technologies for the development of Akt/PKB inhibitors. These technologies are helpful in the development of specific and more effective targeted therapies.

For instance, Denovo Biopharma LLC has developed a technology to design new clinical trials for the failed drug candidates due to their undesirable adverse effects. The technology is enabling the drug candidate to be used in lower dose for small and targeted patient population.

The key objective of this technology is to identify novel biomarkers by scanning human genome to design a specific study for targeted population.

Some of the key players involved in the development of Akt/PKB inhibitors include F. Hoffman-La-Roche Ltd, Eli Lilly & Company, Merck & Co. Inc., Novartis AG, Denovo Biopharma LLC, Diffusion Pharmaceuticals Inc., Astex Pharmaceuticals, ArQule Inc., Cotinga Pharmaceuticals Inc., and Oneness Biotech Co. Ltd.

News From

P&S IntelligenceP&S Intelligence
Category: Market Research Publishers and RetailersCompany about: Prescient & Strategic (P&S) Intelligence Private Limited (formerly known as P&S Market Research Private Limited) was born out of the idea of helping businesses achieve breakthroughs through intelligent decision making, underpinned by a thorough understanding of industry dynamics. As a market intelligence and consulting firm, we strive to provide our clients with first-string market insights to facilitate intelligent decision making.At P&S Intelligence, we offer a multi-dimensional analytical lan ...
This email address is being protected from spambots. You need JavaScript enabled to view it.